鼻腔内薬・ワクチンデリバリーの世界市場(~2027)

• 英文タイトル:Intranasal Drug & Vaccine Delivery Market Research Report by Distribution Channel, Application, Product, Dosage, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

Intranasal Drug & Vaccine Delivery Market Research Report by Distribution Channel, Application, Product, Dosage, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19「鼻腔内薬・ワクチンデリバリーの世界市場(~2027)」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2301G048
• 出版社/出版日:360iResearch / 2022年10月
• レポート形態:英語、PDF、256ページ
• 納品方法:Eメール(受注後2-3日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User(1名利用、印刷可)¥742,350 (USD4,949)▷ お問い合わせ
  Enterprise License(企業利用、印刷可)¥1,492,350 (USD9,949)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
360iResearch社は、世界の鼻腔内薬・ワクチンデリバリー市場規模が、2021年の448.5億ドルから2022年には482.1億ドルへ増加し、2027年までにCAGR 7.75%拡大して702.1億ドルまで成長すると予測しています。本書では、鼻腔内薬・ワクチンデリバリーの世界市場を調査対象とし、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、流通チャネル別(病院薬局、オンライン薬局、小売薬局)分析、用途別(神経障害、疼痛管理、呼吸障害、ワクチン)分析、製品別(送液装置、粉体搬送装置、加圧定量吸入器)分析、投薬量別(複数回投与、単位服用量)分析、地域別(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)分析、競争状況、企業情報などの内容を整理しました。また、本書に記載されている企業情報にはAptarGroup, Inc.、AstraZeneca PLC、Bausch Health Companies Inc、Baxter International, Inc.、Becton, Dickinson, and Company、Bharat Biotech International Limited、GlaxoSmithKline PLC、Intersect ENT、Johnson & Johnson Services Inc、Marina Biotech, Inc.、Merck & Co.、Neurelis Inc.、Novartis International AG、OptiNose, Inc.などが含まれています。
・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト
・世界の鼻腔内薬・ワクチンデリバリー市場規模:流通チャネル別
- 病院薬局チャネルの市場規模
- オンライン薬局チャネルの市場規模
- 小売薬局チャネルの市場規模
・世界の鼻腔内薬・ワクチンデリバリー市場規模:用途別
- 神経障害における市場規模
- 疼痛管理における市場規模
- 呼吸障害における市場規模
- ワクチンにおける市場規模
・世界の鼻腔内薬・ワクチンデリバリー市場規模:製品別
- 送液装置の市場規模
- 粉体搬送装置の市場規模
- 加圧定量吸入器の市場規模
・世界の鼻腔内薬・ワクチンデリバリー市場規模:投薬量別
- 複数回投与における市場規模
- 単位服用量における市場規模
・世界の鼻腔内薬・ワクチンデリバリー市場規模:地域別
- 南北アメリカの鼻腔内薬・ワクチンデリバリー市場規模
アメリカの鼻腔内薬・ワクチンデリバリー市場規模
カナダの鼻腔内薬・ワクチンデリバリー市場規模
ブラジルの鼻腔内薬・ワクチンデリバリー市場規模
...
- アジア太平洋の鼻腔内薬・ワクチンデリバリー市場規模
日本の鼻腔内薬・ワクチンデリバリー市場規模
中国の鼻腔内薬・ワクチンデリバリー市場規模
インドの鼻腔内薬・ワクチンデリバリー市場規模
韓国の鼻腔内薬・ワクチンデリバリー市場規模
台湾の鼻腔内薬・ワクチンデリバリー市場規模
...
- ヨーロッパ/中東/アフリカの鼻腔内薬・ワクチンデリバリー市場規模
イギリスの鼻腔内薬・ワクチンデリバリー市場規模
ドイツの鼻腔内薬・ワクチンデリバリー市場規模
フランスの鼻腔内薬・ワクチンデリバリー市場規模
ロシアの鼻腔内薬・ワクチンデリバリー市場規模
...
- その他地域の鼻腔内薬・ワクチンデリバリー市場規模
・競争状況
・企業情報

The Global Intranasal Drug & Vaccine Delivery Market size was estimated at USD 44.85 billion in 2021 and expected to reach USD 48.21 billion in 2022, and is projected to grow at a CAGR 7.75% to reach USD 70.21 billion by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Intranasal Drug & Vaccine Delivery to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Distribution Channel, the market was studied across Hospital pharmacies, Online pharmacies, and Retail pharmacies.

Based on Application, the market was studied across Neurological disorders, Pain Management, Respiratory disorders, and Vaccination.

Based on Product, the market was studied across Liquid Delivery Device, Powder delivery device, and Pressurized Metered Dose Inhaler.

Based on Dosage, the market was studied across Multi-dose and Unit-dose.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Intranasal Drug & Vaccine Delivery market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Intranasal Drug & Vaccine Delivery Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Intranasal Drug & Vaccine Delivery Market, including AptarGroup, Inc., AstraZeneca PLC, Bausch Health Companies Inc, Baxter International, Inc., Becton, Dickinson, and Company, Bharat Biotech International Limited, GlaxoSmithKline PLC, Intersect ENT, Johnson & Johnson Services Inc, Marina Biotech, Inc., Merck & Co., Neurelis Inc., Novartis International AG, OptiNose, Inc., Pfizer Inc, Recipharm AB, Rexam PLC, Rokote Laboratories Finland Ltd, Teleflex Incorporated, Teva Pharmaceutical Industries Ltd, The 3M Company, and UCB, Inc..

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Intranasal Drug & Vaccine Delivery Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Intranasal Drug & Vaccine Delivery Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Intranasal Drug & Vaccine Delivery Market?
4. What is the competitive strategic window for opportunities in the Global Intranasal Drug & Vaccine Delivery Market?
5. What are the technology trends and regulatory frameworks in the Global Intranasal Drug & Vaccine Delivery Market?
6. What is the market share of the leading vendors in the Global Intranasal Drug & Vaccine Delivery Market?
7. What modes and strategic moves are considered suitable for entering the Global Intranasal Drug & Vaccine Delivery Market?

レポート目次

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of respiratory and neurological diseases
5.1.1.2. Growth in intranasal product development and commercialization
5.1.1.3. Surge R&D investment and efforts in view of COVID-19
5.1.2. Restraints
5.1.2.1. Side effects associated with the use of nasal products
5.1.3. Opportunities
5.1.3.1. Rise in number of prescriptions for non-invasive drug delivery routes
5.1.3.2. Improving healthcare infrastructure and advanced treatment availability in developing economies
5.1.3.3. Technological advancements related to nasal drug delivery systems
5.1.4. Challenges
5.1.4.1. Development challenges such as requirements of large dose of vaccine and administration difficulties through the nasal route
5.2. Cumulative Impact of COVID-19

6. Intranasal Drug & Vaccine Delivery Market, by Distribution Channel
6.1. Introduction
6.2. Hospital pharmacies
6.3. Online pharmacies
6.4. Retail pharmacies

7. Intranasal Drug & Vaccine Delivery Market, by Application
7.1. Introduction
7.2. Neurological disorders
7.3. Pain Management
7.4. Respiratory disorders
7.5. Vaccination

8. Intranasal Drug & Vaccine Delivery Market, by Product
8.1. Introduction
8.2. Liquid Delivery Device
8.3. Powder delivery device
8.4. Pressurized Metered Dose Inhaler

9. Intranasal Drug & Vaccine Delivery Market, by Dosage
9.1. Introduction
9.2. Multi-dose
9.3. Unit-dose

10. Americas Intranasal Drug & Vaccine Delivery Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Intranasal Drug & Vaccine Delivery Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Intranasal Drug & Vaccine Delivery Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion

14. Company Usability Profiles
14.1. AptarGroup, Inc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. AstraZeneca PLC
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Bausch Health Companies Inc
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Baxter International, Inc.
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Becton, Dickinson, and Company
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Bharat Biotech International Limited
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. GlaxoSmithKline PLC
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Intersect ENT
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Johnson & Johnson Services Inc
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Marina Biotech, Inc.
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Merck & Co.
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Neurelis Inc.
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Novartis International AG
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. OptiNose, Inc.
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Pfizer Inc
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Recipharm AB
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Rexam PLC
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Rokote Laboratories Finland Ltd
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Teleflex Incorporated
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Teva Pharmaceutical Industries Ltd
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. The 3M Company
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
14.22. UCB, Inc.
14.22.1. Business Overview
14.22.2. Key Executives
14.22.3. Product & Services

15. Appendix
15.1. Discussion Guide
15.2. License & Pricing




• 英文レポート名:Intranasal Drug & Vaccine Delivery Market Research Report by Distribution Channel, Application, Product, Dosage, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
• 日本語訳:鼻腔内薬・ワクチンデリバリーの世界市場(~2027)
• レポートコード:MRC2301G048お問い合わせ(見積依頼・ご注文・質問)